semaj83/ctmatch_classification huggingface dataset:
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasm Have had stereotactic or ultrasound-guided biopsy with marker placement Have a lesion or biopsy marker that is visible under ultrasound Have a surgical target =< 6 cm from the skin when lying supine Have a discreet surgical target Have a lesion in which the center/focal area is defined Have the ability to understand and the willingness to sign a written informed consent document Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status will not be used as an criterion Ability to understand and the willingness to sign a written informed consent document  Require more than one localization needle for localization of the surgical target (bracket localization) Have undergone previous open surgical biopsy, lumpectomy, or mastectomy in the operative breast Have a prosthesis/implant in the operative breast Have a cardiac pacemaker or defibrillator device Be contraindicated for surgery Be pregnant
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Colonic Polyp All those over the age of 20 years who agree informed consent and who have at least one polyp of eligible size (6-10 mm)  (1) patients taking anticoagulant therapy during the past 1 week of the procedure, (2) known coagulopathy, (3) history of liver cirrhosis, chronic kidney disease, malignancy, inflammatory bowel diseases or significant infectious disease, (4) American Society of Anesthesiology class III or more, and (5) pedunculated polyps and polyps with malignant feature
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Acne Vulgaris Male or female at least 12 years of age and older Written and verbal informed consent must be obtained Subject must have a score of moderate or severe on the Evaluator's Global Severity assessment Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at the screening and baseline visits Subjects must be willing to comply with study instructions and return to the clinic for required visits  Any dermatological conditions on the face that could interfere with clinical evaluations Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive Subjects with a facial beard or mustache that could interfere with the study assessments Subjects who are unable to communicate or cooperate with the Investigator Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subjects safety while participating in the study
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 9.0-999.0,  Acne Vulgaris Male or female at least 9 years of age and older Written and verbal informed consent must be obtained Subject must have a score of moderate or severe on the Evaluator's Global Severity assessment at the screening and baseline visit Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at screening and baseline visits Subjects must be willing to comply with study instructions and return to the clinic for required visits  Any dermatological conditions on the face that could interfere with clinical evaluations Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive Subjects with a facial beard or mustache that could interfere with the study assessments Subjects who are unable to communicate or cooperate with the Investigator Subjects with any underlying disease that the Investigator deems uncontrolled and poses a concern for the subject's safety while participating in the study
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Dermatitis Healthy Subjects with Fitzpatrick Skin Types I, II or III  Subjects with visible skin disease, tattoos, skin condition, or abnormal skin color
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections for Step 1 HIV infected Triple-class antiretroviral treatment, as determined by the site investigator and as defined by all of the following: a) exposure to 2 or more nucleotide reverse transcriptase inhibitors (NRTIs) for at least 3 months each; b) exposure to 2 or more non-boosted protease inhibitors (PIs) for at least 3 months each, or exposure to a dual PI regimen for at least 3 months; and c) exposure to at least 1 non-nucleotide reverse transcriptase inhibitor (NNRTI) for at least 3 months CD4 cell count of at least 50 cells/mm3 within 45 days prior to study entry Viral load of 2000 copies/ml or more within 45 days prior to study entry On current antiretroviral treatment regimen for at least 30 days prior to study entry. If current treatment includes abacavir, abacavir must be discontinued at least 30 days prior to study entry Willing to use acceptable methods of contraception  for Step 1 Pregnant or breastfeeding Allergy or sensitivity to the study drugs and their formulations Diabetes mellitus Cataracts or any measurable loss of vision due to lens opacity Best-corrected visual acuity worse than 20/200 Certain drugs or vaccines within 30 days prior to study entry History of any of the following: kidney disease; serious illness within 14 days prior to study entry; end organ cytomegalovirus infection; Kaposi's sarcoma; cataracts; active herpetic infection or peptic ulcer disease within 12 months; or malabsorption, severe chronic diarrhea, or inability to eat 1 or more meals a day because of chronic nausea, emesis, or abdominal/mouth and throat discomfort Current alcohol or drug abuse that would interfere with adherence to study requirements
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Peptic Ulcer Hemorrhage Patients must be men or non-pregnant women at least 18 years of age Patients who present with a gastric or duodenal ulcer  Patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat pigmented spot; adherent clots not removed by irrigation Patients presenting with active bleeding and/or NBVV at 2 or more separate sites Patients with any severe concomitant diseases, eg, end stage liver or renal disease, or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 0.0-6.0,  Asphyxia Neonatorum Hypoxia Encephalopathy Seizures The infant will be assessed sequentially by A, B and C listed below A. Infants =>36 completed weeks gestation admitted to the NICU with at least one of the following Apgar score of =<5 at 10 minutes after birth Continued need for resuscitation, including endotracheal or mask ventilation, at 10 minutes after birth Acidosis within 60 minutes of birth (defined as any occurrence of umbilical cord, arterial or capillary pH <7.00) Base Deficit =>16 mmol/L in umbilical cord or any blood sample (arterial, venous or capillary) within 60 minutes of birth Infants that meet A will be assessed for whether they meet the neurological abnormality entry (B) by trained personnel B. Moderate to severe encephalopathy, consisting of altered state of consciousness (lethargy, stupor or coma) AND at least one of the following hypotonia abnormal reflexes including oculomotor or pupillary abnormalities  Infants expected to be > 6 hours of age at the time of randomisation Major congenital abnormalities, such as diaphragmatic hernia requiring ventilation, or congenital abnormalities suggestive of chromosomal anomaly or other syndromes that brain dysgenesis
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Peptic Ulcer Male or female non-cirrhotic patients at least 18 years old suspected to bleed from PU Patients with haematemesis and/or hematochezia and/or melena which have been observed by a member of a clinical team (GP, hospital physician, nurse, ...) Either, documented signs of hypovolemia related to the current bleeding episode Or, occurrence of symptoms of hypovolemia  Treatment of the present bleeding episode with somatostatin or its analogues, vasoactive drugs, or endoscopic therapy Any treatment with PPIs (IV or per os) within the last 48 hours preceding randomisation Treatment (endotherapy or pharmacotherapy) for upper gastrointestinal ulcer bleeding in the last 30 days Deficient haemostasis (platelets < 40 x 109/l, international normalised ratio of the prothrombin time > 1.5 (or prothrombin time < 70%), or activated partial thromboplastin time > 40 seconds (or according to the normal ranges validated, from local lab)) Anticoagulant therapy (vitamin K antagonists or heparin including LMW heparins) Terminal stage illness in which endoscopy is contraindicated
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Peptic Ulcer Patient has non-NSAID (non-steroidal anti-inflammatory drugs), non-Helicobacter pylori bleeding peptic ulcer Age > 18 years old Informed consent  Concommitant use of high dose steroid or warfarin New start on non-steroidal anti-inflammatory drugs or aspirin or COX2 inhibitors Renal failure (serum creatinine > 200umol/l) Previous gastric surgery Oesophagitis, esophageal varices Terminal illness or malignancy
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Peptic Ulcer Hemorrhage Clean base ulcer with severe upper GIB (defined as melaena, hematochezia, hematemesis, and/or gross blood in NG lavage), and any one of the following SBP ≤ 90mmHg; P of ≥110 bpm; or orthostatic changes with SBP drops 20mmHg or P increases 20 bpm; or Transfusion of 2 or more units of packed red blood cells within 12 hrs of admission; or A documented HCT drop of at lest 6% from baseline Endoscopically confirmed bleeding from GU, DU, pyloric ulcer, or anastomotic ulcer Pt can either have primary or secondary acute UGI haemorrhage  Bleeding site from lesion other than GU, DU, pyloric or anastomotic ulcer there is more than one type of significant bleeding lesion Documented hx of cirrhosis / portal HT ESRF requiring any form of dialysis Expected or persistent (>24hrs) coagulopathy with INR> 1.5 Platelet count is under 50000/mm3 Aspirin User / Plavix [Clopidogrel] User If the ulcer is neoplastic Cannot obtained consent Age < 18 or is pregnant
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Peptic Ulcer Hemorrhage all consecutive patients admitted for peptic ulcer bleeding (including bleeding anastomotic ulcers) with emergency endoscopy done in 24 hours after admission with Forrest type Ia, Ib, and IIa, IIb age 15 years Written consent available  ulcer bleeding not controlled in first endoscopy Bleeding from malignant ulcer or tumor Bleeding from Dieulafoy lesion/ angiodysplasia Bleeding from injection sclerotherapy ulcer Patient with ASA category 5
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Peptic Ulcer Hemorrhage Age >16 , can obtain written consent Ulcers that require endoscopic therapy with SRH: Forrest I a, Ib, II a and II b  Moribund patients with terminal malignancy Pregnancy Intercurrent ulcer complication that prevents treatment and surgery becomes mandatory such as bulbar stenosis and ulcer perforation
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cardiac Arrest Male or female patients ≥ 18 years Witnessed out-of-hospital cardiac arrest of presumed cardiac origin in which the initial rhythm is ventricular fibrillation, ventricular tachycardia, pulseless electrical activity (PEA) or asystole First attempt at resuscitation (ACLS or CPR) by emergency medical personnel initiated within 15 minutes of collapse Restoration of spontaneous circulation (ROSC) within 60 minutes of collapse Time from restoration of spontaneous circulation to initiation of cooling is ≤ 6 hours Informed consent provided by authorized representative/family member  Temperature of less than 35C on admission Comatose or vegetative state prior to cardiac arrest Positive pregnancy test Purposeful response to verbal commands after ROSC and prior to initiation of hypothermia Evidence of hypotension (MAP<60) for more than 30 minutes after ROSC and prior to initiation of hypothermia Evidence of hypoxia (oxygen saturation<85% despite supplemental oxygen) for more than 15 minutes after ROSC and prior to initiation of hypothermia Terminal illness that preceded the arrest (life expenctancy < 1 year) Patients experiencing cardiogenic shock Patients continuing to experience refractory ventricular arrhythmias at the time of enrollment Patients receiving 2 or more high dose vasopressors
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Shock Mean arterial pressure less than 70 mmHg or systolic pressure less than 100 mmHg persisting despite adequate fluid loading (in example with at least 1000 mL crystalloid or 500 ml colloid) unless central venous pressure (CVP) or pulmonary artery occluded pressure (PAOP) are elevated (e.g. CVP> 12 mmHg or PAOP > 14 mmHg)  Serious arrhythmia such as rapid atrial fibrillation (> 160/min) or ventricular tachycardia Brain death Open label administration of dopamine, norepinephrine, epinephrine or phenylephrine for more than 4hours
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Shock, Traumatic Blunt or penetrating trauma Prehospital Systolic Blood Pressure (SBP) <= 70;OR Prehospital SBP 71-90 AND Hear Rate (HR) ≥108 years of age or older, or 50kg or more if age unknown  Known or suspected pregnancy Age younger than 15 or less than 50kg if age unknown Ongoing prehospital cardiopulmonary resuscitation (CPR) Administration of more than 2000cc crystalloid or any colloid or blood products Severe hypothermia (suspected Temperature less than 28 degrees celsius) Drowning or asphyxia due to hanging Burns Total Body Surface Area (TBSA) more than 20% Isolated penetrating injury to the head Inability to obtain prehospital intravenous access Time of call received at dispatch to study intervention greater than four hours
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Peptic Ulcers Upper Gastrointestinal Bleeding Consecutive patients admitted for upper gastrointestinal bleeding secondary to peptic ulcers that have been successfully treated with endoscopic therapy  Variceal esophageal bleeding Concurrent PPI use Moribund patients
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Hypothermia Heart Arrest Age between 18 and 79 years old Out-of-hospital cardiac arrest (OH-CA) due to a presumed cardiac etiology Delay between OH-CA and return of spontaneous circulation (ROSC) < 60 minutes Delay between ROSC and starting cooling < 240 minutes Patient not obeying verbal command after ROSC and prior to starting cooling Availability of the "CoolGard" device (ALSIUS product)  Do not reanimate order or terminal disease before Known pregnancy Clinical hemorrhagic syndrome or known coagulopathy Contra-indication to device usage (such as femoral venous access impossible) Hypothermia at admission < 30°C Etiology of OH-CA thought to be extra-cardiac (trauma, bleeding or anoxia) In hospital cardiac arrest Refractory shock (need for extra-corporeal life support)
Patient description: A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Nausea Vomiting Cesarean Section Must be pregnant with a single baby Must be at term in their pregnancy (estimated gestational age of at least 38 weeks) Must be scheduled for an elective Cesarean section Must be between 60-70" tall Must be free of severe systemic disease (ASA class I or II)  Contraindication to spinal anesthesia Any allergy to any of the medications included in the study History of pregnancy-induced hypertension or preeclampsia History of preexisting hypertension Diabetes mellitus Hyperemesis gravidum Previous perioperative nausea and vomiting History of motion sickness Women carrying a fetus with a known abnormality will also be excluded from the study